FDA approves use of prostate cancer bill before chemo

The Food and Drug Administration has expanded approval of Johnson & Johnson's prostate cancer pill Zytiga for men with an earlier stage of the disease. The agency says Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group. Read more here.